Maitreya Medica. Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Maitreya Medicare expects a 20%-25% year-on-year revenue growth in existing hospitals over the next 2-3 years.
- Plans include increasing services and expanding bed capacity by 70 to 80 beds, depending on specialty and service design.
- Expansion of the current Vesu, Surat unit and upcoming Valsad unit are part of growth strategy.
- The company aims to introduce more advanced tertiary and quaternary care services like organ transplant, robotic surgeries, and high-end radiotherapies.
- These high-end services are expected to significantly increase the Average Revenue Per Occupied Bed (ARPOB), targeting around Rs. 40,000.
- Additional opportunities for capacity expansion are being explored as they arise.
See what Maitreya Medica. management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no specific mention of any current or upcoming fundraising through debt or equity in the provided transcript.
- The company recently completed an IPO, which has boosted their business and helped fund growth.
- Expansion plans include increasing bed capacity and new hospital units, such as the upcoming Valsad unit.
- The company is focusing on internal growth, service enhancement, and acquisitions like Tulip Health.
- No explicit statements were made regarding raising new debt or equity funds at this time.
See what Maitreya Medica. management said on order book — free account, 30 seconds.
Capex plans
Yes- Maitreya Medicare Limited is planning to expand its current hospital at Vesu, Surat, potentially adding 70 to 80 beds depending on specialty and services.
- The upcoming Valsad unit has received building usage permission; hospital license is expected soon to start operations.
- Equipment for Valsad unit is already ordered and being installed.
- Expansion opportunities are being explored beyond Maharashtra and Gujarat.
- Acquisition of Tulip Health has been made, focusing on preventive and rehabilitative care including elderly care and advanced diagnostics.
- Future capex includes adding advanced tertiary and quaternary care services like organ transplants, robotic surgeries, and high-end radiotherapies to increase ARPOB.
- Expansion plans are based on area need-based studies with typical bed size per hospital between 50 to 100 beds.
Track Maitreya Medica. — get its next earnings analysis in your feed
Margin guidance
Category 3- Expecting 20%-25% year-on-year revenue growth in existing hospitals driven by increased services and bed expansion (70 to 80 beds).
- Future expansions planned with the upcoming Valsad unit and other opportunities to increase capacity.
- ARPOB (Average Revenue Per Occupied Bed) projected to increase by at least 30%, aiming to reach around Rs. 40,000 with addition of advanced tertiary and quaternary care services like organ transplant and robotic surgeries.
- Highest ever quarterly result recorded in Q3 FY24 with 34% year-on-year revenue growth.
- PAT (Profit After Tax) positive at Rs. 1.57 crores with a 13% PAT margin, turning around from negative in the previous year.
- EPS (Earnings Per Share) increased to 2.84 post bonus share issuance.
- Sustained ARPOB growth expected due to introduction of advanced services and better revenue mix.
Order book
How does Maitreya Medica. rank vs peers in Healthcare Services?
Pro featureHow does Maitreya Medica. rank in Healthcare Services?
Compare Maitreya Medica. against every Healthcare Services company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Maitreya Medica.'s management said in earlier quarters
Others in Healthcare Services this season
- Metropolis Healt (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
- Health X Platform Ltd (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
- Shalby Ltd (Q1 FY27)
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…